Search NLS News

Resalis Therapeutics is headquartered in Turin, Italy, with scientific roots originating from Aalborg University in Denmark and Harvard Medical School in the US.

Mucocort has been granted a patent in China for its product/technology, which has previously been approved under the European Patent System (EPC).

Orexo has announced the first participants have been dosed with OX640, an intranasal rescue medication for severe allergic reactions (incl. anaphylaxis) with powder-based epinephrine, in a new study in subjects with allergic rhinitis (hay fever).

AroCell has announcd the publication of a study in the European Urology Open Science journal.

The study was performed at Testa Center in Uppsala, Sweden, in the 10-liter Xcellerex XDR-10 single-use stirred tank bioreactor (Cytiva).

Takara Bio Europe has announced the expansion of its Gothenburg facility with the addition of a custom manufacturing lab, which came into operation on October 1st.

The EU legislation for substances of human origin (SoHOs) has been revised, bringing blood products, tissues and cells under one regulation.

In a financial market that’s still catching its breath after the repeated turmoil of the past few years, many up-and-coming life science companies in the Nordics are struggling to secure investments and bring their product to market.

With the formation of WiLD Norway, Norway becomes the third of the five Nordic countries to launch an organization dedicated to empowering women in life science. Following the footsteps of Women in Life Science Denmark (WILD) and VILDA in Sweden, something big is brewing across the region, drawing global attention from the life science industry. But why here, and why now? To find out, Nordic Life Science Magazine headed to Oslo to speak with the team behind WiLD Norway.

Projects receiving grants from Knut and Alice Wallenberg Foundation includes new, effective, personal cancer immunotherapy and improved protection against infections and viruses.